Slide 1: Hydrix 2020 Annual General Meeting Presentation
ASX Announcement 11/12/2020 Hydrix 2020 Annual General Meeting Presentation Hydrix Limited (Hydrix or the Company) (ASX:HYD) attaches a presentation which will be delivered by the Executive Chairman, Gavin Coote, at Hydrix’s 2020 Annual General Meeting today. -ENDS- This announcement is authorised f
Slide 2: Executive Chairman Update, AGM December 2020
4 Hydrix Limited Hydrix brings technologies to life which enhance people’s health, safety and well-being Executive Chairman Update AGM December 2020
Slide 3: Board & Senior Management Team
5 Board & Senior Management Team Hydrix’s board and leadership teams have the experience and drive to ensure the success of the Company Hydrix Board Gavin Coote Paul Wright Joanne Bryant Julie King Alyn Tai Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Corpo
Slide 4: Hydrix – corporate snapshot
6 Hydrix – corporate snapshot Major Shareholders Shares (m) % Capital Structure (as of 10th December 2020) Ticker HYD John W King Nominees & Associates 18.93 12.2% Share Price $0.28 CS Third Nominees Pty Limited 11.68 7.5% Shares on Issue (m) 155.2 Patagorang Pty Ltd 8.45 5.4% Options and Performanc
Slide 5: Executive Summary
7 Executive Summary • Powerful product innovation company = 200+ client programs over 18 years • Strong FY20 performance = material market valuation uplift post-year end • Innovative medtech and cardiac product focus = significant tail winds for future growth • Strong balance sheet with $9.5m+ cash
Slide 6: Strategy - powering growth and innovation
8 Strategy - powering growth and innovation Modest margin, good cashflow, Higher margin, scalable, large covers group costs, provides leads market opportunity Hydrix Services Hydrix Medical Leveraging powerful Hydrix Group’s powerful Diagnostic, monitoring & product innovation to product innovation
Slide 7: FY20 Quarterly milestone achievements
9 FY20 Quarterly milestone achievements Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 AngelMed Development Distribution Agreement Acquires Exclusive Rights Impact of COVID-19 Hydrix Services & Angel Medical Hydrix Medical enters binding Hydrix Medical completes COVID-19 requires work from Systems Inc. (“AngelMed”
Slide 8: FY20 financial achievements
10 FY20 financial achievements Strategic initiatives & strong FY20 performance setup recent share price and market valuation uplift Significant Company performance on key metrics compared to the prior year SG implants announced • Group revenues up 12% to $15.9 million (FY19 $14.2 million) 0.60 • Cor
Slide 9: Hydrix Services business overview
11 Hydrix Services business overview 43% growth We develop products that Unique people delivering 1H20 revenue growth prior to COVID-19 transform industries outstanding results $18.0 $15.7 million Total Revenues $15.7M $16.0 $13.5M $14.0 16% YoY Growth $12.0 2H $7.5 $1.2M $10.0 2H $7.8 $8.0 Cash ope
Slide 10: Hydrix Services project examples
12 Hydrix Services project examples Cardiac technologies Life Sciences Industrial & Mining Various early-stage cardiac technology Hydrix and our client, Memphasys, won two We undertook new mining and industrial projects to develop external controllers Good Design Awards for the FELIX, an IVF project
Slide 11: Hydrix Medical – a cardiac monitoring & intervention vision
13 Hydrix Medical – a cardiac monitoring & intervention vision Cardiovascular Disease (CVD); a chronic & expensive health issue Connected Patient Monitoring Globally: Patient • Impacts 14% of population Monitoring Cardiac monitoring • Is the leading cause of devices communicate to smart phone or ext
Slide 12: Hydrix Medical – multiple product revenue & margin opportunities
14 Hydrix Medical – multiple product revenue & margin opportunities Bringing world-first cardiac devices to the APAC market Revenue potential AngelMed Guardian – World First Implantable 24X7 Continuous Heart Monitor • An implantable continuous heart monitoring device that detects cardiac events, ~3%
Slide 13: Hydrix Ventures – picking high potential winners
15 Hydrix Ventures – picking high potential winners Generating equity returns investing in high potential clients AngelMed Guardian Gyder Surgical Memphasys (ASX: MEM) Cyban 4.6% equity up to 15% equity <1.0% equity 7.5% equity Investment considerations include: (i) Hydrix Services client, (ii) high
Slide 14: Investor Relations Programs – significant increase in market awareness
16 Investor Relations Programs – significant increase in market awareness Increased media following: • 30+ news media stories and business network interviews in past 6 months • 2nd shareholder newsletter distributed • 41% increase in website enquiries & leads • 28% increase in social media followers
Slide 15: 1H FY21 to-date financial update
17 1H FY21 to-date financial update • Services revenue pipeline remains healthy at $50+ million, anticipate stronger 2HF21 & beyond • Anticipate full year FY21 cash operating breakeven of core business • Proactively managing variable and discretionary operating costs in line with revenues • 1QFY21 r
Slide 16: Potential news flow July 2020 through December 2021
18 Potential news flow July 2020 through December 2021 Anticipated news events calendar Q1 FY21 Actual Q2 FY21 Actual Q3 FY21 Q4 FY21 1H FY22 • Completed five sales • Announced exclusive rights to • AngelMed USA submission of • Potential FDA approval of • Potential AngelMed (implants) of AngelMed di
Slide 17: Investor value creation – high potential from material product revenue growth
19 Investor value creation – high potential from material product revenue growth • Powerful product innovation company • Multiple growth platforms • Significant tail winds for innovative medtech and cardiac products • COVID accelerating ‘real time’ monitoring and management of cardiac disease • Well
Slide 18: Disclaimer
20 Disclaimer This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Com